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Abstract
Background: Patients with multiple sclerosis (MS) have a decreased frequency of CD8
+ T cells reactive to their own
Epstein-Barr virus (EBV) infected B cells. We have proposed that this might predispose to the development of MS by
allowing EBV-infected autoreactive B cells to accumulate in the central nervous system. The decreased CD8
+ T cell
response to EBV results from a general CD8
+ T cell deficiency and also a decreased proportion of EBV-specific T cells
within the total CD8
+ T cell population. Because decreased HLA class I expression on monocytes and B cells has been
reported in MS and could influence the generation and effector function of EBV-specific CD8
+ T cells, the present
study was undertaken to measure the expression of HLA molecules on B cells and monocytes in patients with MS.
Methods: We used flow cytometry to determine the proportions of T cells, natural killer cells, B cells and
monocytes in peripheral blood mononuclear cells (PBMC) and to quantify the expression of HLA molecules on T
cells, B cells and monocytes of 59 healthy subjects and 62 patients with MS who had not received corticosteroids
or immunomodulatory therapy in the previous 3 months.
Results: The levels of HLA class I and class II molecules expressed on T cells, B cells and monocytes were normal
in patients with MS, with the exception of two patients with secondary progressive MS with very low class II
expression on B cells. In confirmation of previous studies we also found that the percentage of CD8
+ T cells was
significantly decreased whereas the percentage of CD4
+ T cells and the CD4:CD8 ratio were significantly increased
in patients with MS compared to healthy subjects.
Conclusions: The decreased CD8
+ T cell response to EBV-infected B cells in MS patients is not due to decreased
HLA class I expression on monocytes or B cells. In a small proportion of patients decreased HLA class II expression
on B cells might impair the CD8
+ T cell response to EBV by reducing CD4
+ T cell help.
Background
A large body of evidence indicates that infection with
the Epstein-Barr virus (EBV) has a role in the pathogen-
esis of multiple sclerosis (MS) [1-3]. Several hypotheses
have been proposed to explain the role of EBV in the
development of MS, including immunological crossreac-
tivity between EBV and central nervous system (CNS)
antigens [4], autoimmunity to aB-crystallin [5], EBV
infection of autoreactive B cells [6], bystander damage
from immune attack against EBV in the CNS [7], and
interactions with other infectious agents such as human
endogenous retroviruses [8]. It is important to deter-
mine the role of EBV in the pathogenesis of MS because
of the potential to prevent and treat MS by controlling
EBV infection, such as by vaccination against EBV [9].
In particular it is necessary to understand the exact rela-
tionship between EBV and the immune system in MS in
order to ensure that these interventions are beneficial,
not harmful.
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EBV-specific immune responses, especially by cytotoxic
CD8
+ T cells which eliminate proliferating and lytically
infected B cells [10]. We have hypothesized that a
genetically determined defect in the elimination of EBV-
infected B cells by cytotoxic CD8
+ T cells might predis-
pose to the development of MS by allowing EBV-
infected autoreactive B cells to accumulate in the central
nervous system [3,6]. Studies of CD8
+ T cell reactivity
to EBV using selected synthetic EBV peptides to stimu-
late the T cells have produced conflicting results, with
reports of normal reactivity [11] and increased reactivity
[12] in clinically isolated syndromes, and normal reactiv-
ity [12,13] and increased reactivity [14] in established
MS. Studies using selected EBV peptides to assess T cell
reactivity are limited by the fact that they do not pro-
vide a measure of the total T cell response to EBV,
which encodes many different proteins. To overcome
this it is necessary to measure the T cell response to
autologous EBV-infected B cells. This provides a direct
measure of the aggregate T cell response to EBV-
infected B cells in each subject because it uses each per-
son’s natural antigen-processing mechanisms to present
viral antigens at normal physiological concentrations on
the surface of their own EBV-infected B cells and it
represents the total T cell response to all EBV antigens
presented by all HLA molecules on infected B cells in
each subject [15]. Using this approach we have shown
that patients with MS have a decreased frequency of
CD8
+ T cells reactive to their own EBV-infected B cell
lymphoblastoid cell lines (LCL) [15]. This results from a
general CD8
+ T cell deficiency and also a decreased pro-
portion of EBV-specific T cells within the total CD8
+ T
cell population [16]. Our finding of decreased CD8
+ T
cell reactivity to LCL in patients with MS [15] differs
f r o map r e v i o u ss m a l ls t u d yo n1 1p a t i e n t sw h i c h
reported a non-significant increase in the frequency of
LCL-specific CD8
+ T cells [17], but is consistent with
an early report of decreased T cell control of LCL out-
growth [18] and a recent report of a trend (p = 0.07)
towards a decreased CD8+ T cell response to LCL [19].
In view of a previous report of decreased HLA class I
expression on monocytes and B cells in patients with
MS [20], which could impair the generation and effector
function of EBV-specific CD8
+ T cells, we have underta-
ken the present study to quantify the level of HLA




Blood was collected from 59 healthy subjects and 62 MS
patients following informedc o n s e n t .T h i ss t u d yw a s
approved by the Royal Brisbane & Women’sH o s p i t a l
Human Research Ethics Committee and The University
of Queensland Medical Research Ethics Committee. All
patients met the 2005 Revised McDonald Criteria for a
diagnosis of MS [21]. The clinical course was relapsing-
remitting (RRMS) in 23 patients, secondary progressive
(SPMS) in 25 and primary progressive (PPMS) in 14.
The patients had not received corticosteroids or immu-
nomodulatory therapy for at least 3 months prior to
venesection. Only two patients had ever received immu-
nosuppressive drugs and these had been ceased four
years before blood collection. An additional 7 patients
had received interferon-b which had been ceased 6
months to 6 years before blood collection. Disability was
assessed using the Kurtzke Expanded Disability Status
Scale (EDSS) [22], and the MS Severity Score (MSSS)
was determined from the EDSS and disease duration
[23]. The demographic and clinical details of the healthy
subjects and patients with MS are presented in Table 1.
Flow cytometry
Peripheral blood mononuclear cells (PBMC) were sepa-
rated by density centrifugation and cryopreserved, as
previously described [15]. PBMC samples were thawed
and cultured for 24 h to allow cells to rest and re-
express cell surface receptors. Propidium iodide staining
demonstrated > 99% viability within the lymphocyte and
monocyte forward scatter/side scatter gate for each sam-
ple used. PBMC samples were assessed using a Becton











Age (years) 40.4 ± 10.8 45.5 ± 12.1 38.0 ± 9.7 50.8 ± 10.1 48.2 ± 13.3
Sex (% female) 67.8 69.3 73.9 68.0 64.3
Age of onset of MS (years) 33.5 ± 9.6 31.4 ± 10.6 33.4 ± 8.3 36.9 ± 9.7
Duration of MS (years) 12.8 ± 8.4 7.6 ± 6.5 18.0 ± 7.7 11.9 ± 7.1
EDSS score 5.1 ± 2.3 3.1 ± 1.8 6.3 ± 1.9 6.1 ± 1.6
MSSS 6.2 ± 2.6 4.9 ± 2.8 6.9 ± 2.4 7.4 ± 1.9
All values except for sex presented as mean ± standard deviation.
HC: healthy control subjects, All MS: total group of MS patients, RRMS: relapsing-remitting MS, SPMS: secondary progressive MS, PPMS: primary progressive MS,
EDSS: Expanded Disability Status Scale, MSSS: MS Severity Score.
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killer (NK) cells, CD19
+ B cells and CD14
+ monocytes
within the combined lymphocyte and monocyte gates.
To quantify expression of HLA class I or class II mole-
cules, PBMC were co-stained with either anti-HLA-ABC
or anti-HLA-DR/DP/DQ in combination with anti-CD3
(T cells), anti-CD19 (B cells) or anti-CD14 (monocyte)
antibodies. HLA-DR expression was also measured in 30
of the healthy subjects and 33 of the MS patients. Cali-
brite beads (BD Pharmingen) and FACSComp software
were used daily to ensure calibrated, comparable mea-
surement of geometric mean fluorescence intensity
(MFI). Antibodies were directly conjugated to allophyco-
cyanin (anti-CD3, anti-CD19 and anti-CD14), R-phy-
coerythrin (anti-CD4, anti-CD8, anti-CD16 and anti-
CD56) or fluorescein isothiocyanate (anti-HLA-ABC,
anti-HLA-DR/DP/DQ and anti-HLA-DR) (BD Pharmin-
gen, San Diego, California, USA). CellQuest software
(BD Biosciences) was used for acquisition and analysis
of flow cytometry data.
Data analysis and statistics
Statistical analyses were performed using GraphPad
Prism version 5.04 (Graphpad Software Inc., San Diego,
California, USA, http://www.graphpad.com). For com-
parisons between the whole group of MS patients and
healthy subjects, Student’s t test or the Mann-Whitney
rank sum test was used, according to the distribution of
the data. For comparison between each of the subtypes
of MS (RRMS, SPMS and PPMS) and healthy subjects,
one-way analysis of variance with Dunnett’st e s tf o r
multiple comparisons was used. The CD4:CD8 ratios
were log transformed to make the distributions approxi-
mately normal prior to analysis. Differences were con-
sidered significant for p < 0.05.
Results
Table 2 shows the proportions of lymphocytes and
monocytes in the peripheral blood. The percentages of
CD3
+ T cells, NK cells, B cells and monocytes were nor-
mal in the total group of MS patients, as well as in the
RRMS, SPMS and PPMS subgroups, with the exception
of an increased percentage of CD3
+ T cells in PPMS.
The percentage of CD8
+ T cells was significantly
decreased whereas the percentage of CD4
+ T cells and
the CD4:CD8 ratio were significantly increased in the
total group of MS patients compared to healthy subjects;
these changes were more pronounced in SPMS and
PPMS than in RRMS. The levels of expression of HLA
class I molecules on T cells, B cells and monocytes were
normal in the total group of MS patients and in the
RRMS, SPMS and PPMS subgroups (Table 2). Analysis
of HLA class I expression with the W6/32 antibody
used by Li and colleagues [20]a l s od e m o n s t r a t e dn o r -
mal HLA class I expression on lymphocytes and mono-
cytes in the MS patients (data not shown). The levels of
HLA class II expression on T cells, B cells and mono-
cytes were also normal in the total group of MS
patients, as well as in the RRMS, SPMS and PPMS sub-
groups (Table 2), with the exception of very low levels
of B cell expression (MFI = 1077 and 1139) in 2 patients
with SPMS. HLA-DR expression on B cells was also
assessed in one of these 2 patients and found to be very
low (MFI = 2404). HLA-DR expression on B cells and
monocytes was otherwise normal in the MS patients
tested (Table 3).
Discussion
I nt h ep r e s e n ts t u d yw eh a v ef o u n dt h a tp a t i e n t sw i t h
MS have normal expression of HLA class I molecules
on T cells, B cells and monocytes. Our findings stand in
contrast to a previous study reporting low levels of HLA
class I expression on T cells, B cells and monocytes in
MS patients [20], but are consistent with a report of
normal HLA class I expression on monocytes in MS
[24] and with our previous finding of normal HLA class
I expression on EBV-infected LCL in MS patients [15].
We therefore conclude that the decreased CD8
+ T cell
response to EBV-infected B cells in MS patients [15,16]
is not due to decreased HLA class I expression on
monocytes or B cells.
We also found normal expression of HLA class II
molecules on T cells, B cells and monocytes in patients
with MS, with the exception of two patients with SPMS
who had very low class II expression on B cells. Low B
cell HLA class II expression might impair the CD8
+ T
cell response to EBV by reducing CD4
+ T cell help,
which normally stimulates the expansion of EBV-specific
CD8
+ T cells by producing interleukin-2 [25]. Our find-
ing of normal HLA-DR expression on monocytes in MS
is consistent with the report of Kouwenhoven and col-
leagues [24].
Our findings of an increased proportion of CD4
+ T
cells, a decreased proportion of CD8
+ T cells and an
increased CD4:CD8 ratio in the blood of patients with
MS are consistent with previous studies [18,26-33]. Our
observation that CD8
+ T cell deficiency is more marked
in SPMS and PPMS than in RRMS corroborates pre-
vious studies reporting that the decrease in CD8
+ T
cells is most pronounced in progressive MS [29-31]. We
did not measure the absolute counts of CD4
+ Tc e l l s
and CD8
+ T cells but previous studies have shown that
the absolute number of CD4
+ T cells is normal and the
absolute number of CD8
+ T cells is decreased in MS
[30,32,33]. Future studies should be directed towards
determining the cause of the CD8
+ T cell deficiency,
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CD8 T cell ratio is genetically controlled [34], with at
least some of the responsible genes being located in the
HLA complex [35]. CD8
+ T cell deficiency is a feature
of many chronic autoimmune diseases and is also found
in healthy blood relatives of patients with autoimmune
diseases [36-38], indicating that it is genetically deter-
mined and not secondary to the disease process.
Conclusions
The decreased CD8
+ T cell response to EBV-infected B
cells in MS patients is not due to decreased HLA class I












+ T cells 72.8 ± 0.8 74.4 ± 1.0 74.2 ± 1.5 72.2 ± 1.7 78.9 ± 1.5
p value 0.216* < 0.05
% CD4
+CD3
+ T cells 46.2 ± 1.1 52.2 ± 1.2 49.7 ± 1.9 51.1 ± 1.8 58.1 ± 1.9
p value < 0.001* < 0.05 < 0.001
% CD8
+CD3
+ T cells 23.1 ± 0.8 19.8 ± 0.7 21.7 ± 1.1 18.8 ± 1.0 18.3 ± 1.6
p value 0.007† < 0.01 < 0.05
CD4:CD8 ratio 2.2 ± 0.1 3.0 ± 0.2 2.5 ± 0.2 3.0 ± 0.3 3.7 ± 0.5
p value < 0.001† < 0.01 < 0.001
% NK cells 8.1 ± 0.6 8.1 ± 0.6 9.1 ± 1.1 8.0 ± 1.1 6.5 ± 1.0
p value 0.553†
% B cells 13.1 ± 0.6 11.7 ± 0.7 11.1 ± 1.1 13.0 ± 1.1 10.5 ± 1.1
p value 0.143*
% monocytes 7.7 ± 0.6 7.6 ± 0.6 8.2 ± 1.1 8.1 ± 1.0 5.4 ± 1.0
p value 0.752†
T cell HLA class I MFI 2015 ± 60 2072 ± 46 1964 ± 61 2082 ± 73 2223 ± 107
p value 0.445*
T cell HLA class II MFI 14.0 ± 0.5 13.7 ± 0.6 13.3 ± 0.8 13.3 ± 0.7 15.0 ± 1.7
p value 0.406†
B cell HLA class I MFI 3838 ± 132 4063 ± 123 4037 ± 231 3919 ± 164 4362 ± 261
p value 0.214*
B cell HLA class II MFI 4384 ± 146 4273 ± 153 4313 ± 210 3951 ± 265 4784 ± 315
p value 0.605*
Monocyte HLA class I MFI 4948 ± 221 4941 ± 189 4823 ± 282 4837 ± 355 5322 ± 297
p value 0.982*
Monocyte HLA class II MFI 2587 ± 218 2907 ± 236 3053 ± 418 2578 ± 317 3254 ± 561
p value 0.474†
All values presented as mean ± standard error.
PBMC: peripheral blood mononuclear cells, HC: healthy control subjects, All MS: total group of MS patients, RRMS: relapsing-remitting MS, SPMS: secondary
progressive MS, PPMS: primary progressive MS, NK: natural killer, MFI: mean fluorescence intensity.
All p values are for comparisons with HC, using either Student’s t test* or the Mann-Whitney rank sum test† for the comparison with All MS, and using one-way
analysis of variance with Dunnett’s test for multiple comparisons for comparisons with RRMS, SPMS and PPMS; p values < 0.05 are considered significant. In the
right three columns of the table, p values are corrected for multiple comparisons using Dunnett’s test and are > 0.05 unless otherwise indicated. The CD4:CD8
ratios have been log transformed to make the distributions approximately normal prior to analysis.











B cell HLA-DR MFI 4745 ± 127 4729 ± 147 4894 ± 209 4489 ± 279 4974 ± 135
p value 0.940 > 0.05 > 0.05 > 0.05
Monocyte HLA-DR MFI 4122 ± 337 4321 ± 314 4657 ± 683 4122 ± 384 4273 ± 729
p value 0.655 > 0.05 > 0.05 > 0.05
All values presented as mean ± standard error.
HC: healthy control subjects; All MS: total group of MS patients, RRMS: relapsing-remitting MS, SPMS: secondary progressive MS, PPMS: primary progressive MS,
MFI: mean fluorescence intensity.
All p values are for comparisons with HC, using the Mann-Whitney rank sum test for the comparison with All MS, and using one-way analysis of variance with
Dunnett’s test for multiple comparisons for comparisons with RRMS, SPMS and PPMS; p values < 0.05 are considered significant.
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tion of patients decreased HLA class II expression on B
cells might impair the CD8
+ T cell response to EBV by
reducing CD4
+ T cell help.
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